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AN INSTITUTIONAL PERSPECTIVE ON THE EFFICACY OF DONOR LEUKO-
CYTE INFUSIONS FOR PATIENTS WITH POST-TRANSPLANT RELAPSE
Myers, L.1, Burmeister, J.1, Mater, E.1, Murray, S.1, Curtin, P.T.2,
Gajewski, J.L.1, Hayes-Lattin, B.1, Kovacsovics, T.1, Leis, J.F.3,
Meyers, G.1, Slater, S.1, Maziarz, R.T.1 1Oregon Health and Science
University, Portland, OR; 2University of California San Diego, San
Diego, CA; 3Mayo Clinic Hospital, Scottsdale, AZ
Patients with post-allogeneic HSCTdisease relapse can be treated
with salvage chemotherapy but are also candidates for immune sup-
pression withdrawal and/or donor lymphocyte infusion (DLI).
A total of 237 adult patients experienced relapse of disease post-al-
logeneic transplant at our institution between 1995 and 2010. A ret-
rospective institutional analysis was performed on the 52 patients
who received DLI in that timeframe. The DLI product infusion
doses ranged from 0.07 to 4.0 x 108 CD3+ cells.
CML patients had the most favorable DLI response rates with
78% (n 5 7) in remission at 3 years. Patients with relapsed AML/
MDS and lymphoid malignancies fared worse with 36% and 21%
OS at 3 years respectively. OS was superior in patients in CR prior
to DLI (45%) compared to those with active disease (5%) and for pa-
tients under the age of 50 (32% vs 21%). Three year OS was ob-
served of 5% for patients who relapsed prior to day +100, 29% for
relapse between day +100 and 1 year, and 59% for relapse after 1
year. Patients who developed GvHD prior to relapse had a 3 year
OS of 35% vs 9% in patients without GvHD. Patients with post-
DLI GvHD had a 39%OS vs 11% for patients without GvHD after
DLI. No difference in post-DLI survival was noted with regards to
pre-transplant disease status, cell dose or transplant conditioning.
CML patients respond well to DLI however in the TKI era, trans-
plants for these patients are reserved for patients with TKI-resistant
disease. In other patients, immune suppression withdrawal and DLI
have limited efficacy for those who do not achieveCR post-relapse or
who relapse within 3 months of transplant. These patients are in
need of alternative treatment strategies.394
PRECONDITIONING WITH RAPAMYCIN AND CTLA4-Ig IN DOGS GIVEN
DONOR ANTIGEN AND 1Gy TOTAL BODY IRRADIATION (TBI) BEFORE
DOG-LEUKOCYTE-ANTIGEN (DLA)-IDENTICAL MARROW TRANSPLAN-
TATION FAILED TO ASSURE SUSTAINED ENGRAFTMENT
Wang, Z.1,2, Sorror, M.L.1,2, McCune, J.S.1,3, Butts, T.1,
Graves, S.G.1,2, Storb, R.1,2 1Fred Hutchinson Cancer Research Center,
Seattle, WA; 2University of Washington, Seattle, WA; 3University of
Washington, Seattle, WA
Stable engraftment of allogeneic, DLA-identical marrow can be
achieved by conditioning dogs with a nonmyeloablative dose of 2
Gy TBI followed by a brief course of postgrafting immunosuppres-
sion with cyclosporine (CSP) and mycophenolate mofetil (MMF).
However, when TBI dose was reduced to 1 Gy, CSP/MMF failed to
control host-versus-graft (HVG) reactions, and grafts were uniformly
rejected. CTLA4-Ig blocks T-cell costimulation through the
B7:CD28 signaling pathway and induces T cell anergy. We used
CTLA4-Ig concurrently with infusion of donor peripheral blood
mononuclear cells (PMBC) to blunt activated recipient T cells before
transplantation (Storb et al., Blood 94, p2523-2529, 1999). The regi-
men was effective in establishing stable mixed chimerism in67% of
the animals. Rapamycin mediates immunosuppression by inhibiting
both cytokine driven pathways and costimulatory signaling, and has
been reported to act in synergy with CTLA4-Ig for tolerance induc-
tion in solid organ transplantation. In the current study we asked
weather adding rapamycin to CTLA4-Ig before transplantation
would improveour earlier results and further aid in sustaining engraft-
ment. Accordingly, six recipient dogs were given CTLA4-Ig on days
-7 to -1 and rapamycin on days -6 to -2, with concurrent intravenous
administration of 10^6 (n5 2) or 10 x 10^6 (n5 4) PBMC from their
respective DLA-identical donors from days -7 to -1 before 1Gy TBI,
and CSP/MMF after marrow transplantation. The regimen was well
tolerated and all 6 dogs showed initial allogeneic engraftment. Only
one dog showed persistent mixed chimerism for more than 34 weeks
while 5 dogs rejected their allografts between 8 to 12 weeks followed
by autologous marrow recovery, a timing that was comparable to thatin control dogs. These findings illustrate the difficulty to achieve uni-
form sustained engraftment in DLA-identical dogs using pharmaco-
logical immunosuppression in combination with 1 Gy TBI.395
EVALUATION OF HCT-CI COMORBIDITY SCORES AND ALLOGENEIC
TRANSPLANT OUTCOME OF YOUNG ADULTS AFTER MYELOABLATIVE
CONDITIONING WITH FLUDARABINE AND BUSULFAN +/- TBI MALIG-
NANCIES
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We have previously reported an association between HCT-CI
scores 1 and more and increased TRM in allogeneic patients older
than 50 years. Now, we have analyzed HST-CI in 411 consecutive
younger patients with hematologic malignancy transplanted be-
tween 1999 and 2008.
Two hundred and thirty four patients had low-risk disease (ALCR
1 or 2, CMLCP), all others were considered high-risk. The myeloa-
blative regimen included fludarabine 250mg/m2 and intravenous bu-
sulfan 12.8mg/kg, 203 patients (49.4%) received additional TBI
(400cGy). CsA, MTX and Thymoglobulin (4.5mg/kg) were given
for GVHD prophylaxis. Donors were matched siblings in 208 cases
(50.6%); bone marrow, peripheral and umbilical blood were used in
73 (17.8%), 327 (79.5%) and 11 (2.7%) patients, respectively. Me-
dian age was 40 years (range 16-50) and median follow-up was 38
months (1-148 mo).
HCT-CI scoreswere0 in287 (70%), 1 in68 (16.5%),2 in27 (6.5%),
3 in22 (5.3%) and4 in7 (1.7%)patients.TRMofpatientswith score 0,
1, 2, or 3+was 13%, 12%, 33%and10%at1 year (p50.022) and14%,
15%, 33% and 14% at 3 years (p5 0.074), respectively.
Multivariate analysis only demonstrated an association of TRM
with HCT-CI score 2 (SHR 5 2.75; 95%CI: 1.27-5.98; p 5 0.01).
Three other factors were also significant: CMV status (SHR 5
2.02; 95%CI 1.1-3.71; p 5 0.024), alternative donor (SHR 5 1.95;
95%CI 1.17-3.25; p 5 0.010) and age (SHR 5 1.03 per year; 95%
CI 1.0-1.07; p 5 0.042).
Conclusions:
1. In contrast to older patients, the TRM of the combined group of
patients given a score of 1 and more was no different from those
with a score of 0.
2. Patients with score of 2 had significantly higher TRM.
3. Scores of 3 and 4 mostly represented previous malignancies and
pulmonary disease and did not seem to influence TRM in these
patients.
4. Increasing HCT-CI scores did not accurately reflect increasing
TRM in young patients treated with this regimen.396
PLATELET REFRACTORINESS IS ASSOCIATED WITH DELAYED PLATELET
ENGRAFTMENT AND INCREASED GRAFT VERSUS HOST DISEASE FOL-
LOWING PERIPHERAL BLOOD OR BONE MARROW DERIVED STEM
CELL TRANSPLANTATION
Gandhi, M.J., Schneider, B.A., Jenkins, S., Hogan, W.J., Litzow, M.R.,
Gastineau, D.A., Stubbs, J.R., Patnaik,M.S.Mayo Clinic, Rochester,MN
Background: Platelets (PLT) play a role in innate and adaptive im-
munity and possess pro-inflammatory, as well as pro-thrombotic
properties. PLT transfusion is associated with transfusion immuno-
modulation, resulting in alteration of the recipients’ immune func-
tion. Multiple PLT transfusions may result in alloimmunization
leading to refractoriness and greater transfusion requirements.
PLT refractoriness is relatively more common in patients undergo-
ing stem cell transplantation (SCT) for hematologic malignancies.
We analyzed the clinical outcomes in SCT patients with PLT
refractoriness.
